Constantino Mendieta MD, 4 Beauty Aesthetic Institute for Plastic Surgery has been awarded #1 on Newsweek's list of America's Best Plastic Surgeons 2022. This prestigious award is presented by Newsweek and Statista Inc., the world-leading statistics portal and industry ranking provider. The awards list was announced on June 15, 2022 and can currently be viewed on Newsweek's website.
America's Best Plastic Surgeons 2022 recognizes the best plastic surgeons in the U.S. concentrating on four major procedures: Breast Augmentation, Liposuction, Eyelid Surgery, Facelift, and Rhinoplasty. Statista invited over 2,000 medical experts (doctors/surgeons, plastic surgery clinic managers & health care professionals) to participate in an online survey. The rankings feature the top 150 plastic surgeons for Breast Augmentation, Liposuction, Facelift, and Rhinoplasty. 100 plastic surgeons were awarded for eyelid surgery. Our complex methodology ensures the quality and validity of the ranking. The evaluation process was comprised of two steps:
In-State and Out-of-State recommendations: an independent national survey which resulted in more than 5,900 recommendations from doctors/surgeons, plastic surgery clinic managers & health care professionals with knowledge of plastic surgery.
Quality Score: Additionally, participants were asked to rank the quality dimensions which influence the quality of plastic surgeons. Participants were asked to differentiate between these variables:
• Quality of care
• Continuity of care
• Quality of technical equipment
Certification: Plastic Surgeons receive a 5% bonus on their score if they have a American Board of Plastic Surgery (ABPS) certification
Constantino Mendieta MD, 4 Beauty Aesthetic Institute for Plastic Surgery is ecstatic to be recognized on Newsweek's list of America's Best Plastic Surgeons 2022.
Constantino Mendieta MD, 4 Beauty Aesthetic Institute for Plastic Surgery can be contacted via email, phone, website and Instagram.
4 Beauty Aesthetic Institute for Plastic Surgery
Dr. Constantino Mendieta
Press Release Service by Newswire.com
Original Source: Dr. Constantino Mendieta Awarded #1 on Newsweek's America's Best Plastic Surgeons 2022 List
Mira Ovum Wands
Mira launches Ovum Wand to detect FSH in urine
The FDA has listed Mira's new Mira Ovum Wand as an over-the-counter tool to detect the follicle-stimulating hormone (FSH) in urine. Starting October 2022, the product will be available to U.S. customers. The wands help monitor FSH levels to predict approaching menopause. They can also be used to monitor fertility and find possible causes of reproductive issues for women after 35.
Menopause has been a taboo subject for many generations. The lack of relevant education results in numerous misconceptions about this time in women's lives. Studies show that to this date, one-third of women do not research the topic before they experience menopause. A survey of 1,039 American women ages 40-65 finds that 45% of them didn't know the distinction between perimenopause and menopause. The Mira Ovum Wand can provide information to help understand perimenopause, predict menopause and address the symptoms early. FSH tracking can also help track the effectiveness of hormone replacement therapy to make it more targeted and personalized.
Tracking the follicle-stimulating hormone is essential for women in their 20s, 30s, or 40s because it directly impacts their ability to get pregnant. To predict approaching menopause or track changes in fertility, a person needs to test over several days for two or more cycles. Mira allows users to safely and regularly monitor their FSH levels at home without the need for constant and painful blood tests. And unlike FSH test strips, Mira provides lab-accurate numbers and data points that are saved and analyzed to give users personalized health insights. Users can also choose to share this data with their medical provider.
"The Mira Ovum Wand further expands our capabilities in at-home hormone testing. We can now provide accurate lab-like results for LH, E3G, PdG, and FSH. The launch reinforces Mira's goal to support women throughout their lives by helping them understand their hormones at any age, be it puberty, adulthood, or later years. This knowledge grants the ability to make informed fertility decisions and eliminates the dread associated with the word "menopause." So, women can go through this journey with confidence and awareness," says Sylvia Kang, CEO of Mira.
Mira offers a whole line of hormone test wands, including Mira Fertility (luteinizing hormone), Mira Fertility Plus (estrone-3-glucuronide and luteinizing hormone) and Mira Confirm (pregnanediol glucuronide). Like its predecessors, the new Mira Ovum Wand is compatible with the Mira Analyzer. This high-precision testing device uses machine learning to track changing hormone patterns over time, making Mira more effective than regular ovulation strips. The analyzer can be connected to Mira App to display clear numerical data along with personalized insights on the user's reproductive health.
Mira is the first at-home test to offer a personalized and lab-quality tracking system for monitoring women's reproductive health. It uses patented AI algorithms to accurately measure the levels of major hormones in a woman's urine to provide a holistic view of a woman's reproductive health. Mira is FDA-listed, clinically approved, and OB-GYN recommended.
For more information on Mira, please visit miracare.com.
Press contact: | [email protected] |
Press Release Service by Newswire.com
Original Source: Mira Launches Ovum Wand to Predict Menopause and Monitor Fertility Status for Women Over 35
Tribun Health Releases a New Version of the Next-Generation Telepathology Solution for Remote Case...
Tribun Health Appoints Ludovic d’Apréa as Chief Customer Officer and Strengthens Its C-Level Global...
PARIS, May 25, 2022 (Newswire.com) - Tribun Health today announced the appointment of Ludovic d'Apréa as Chief Customer Officer (CCO) of the Company, in charge of global sales and operations, including projects implementation and customer care. Ludovic has a proven track record as a global leader of motivating and developing strong teams while driving complex change, putting a strong set of operational processes in place and achieving growth & turnaround in the business, all within highly competitive industries such as healthcare IT and medical imaging equipment.
Prior to joining Tribun Health, Ludovic led the Enterprise Diagnostic Informatics business of Philips Healthcare. He joined the Company as part of the acquisition of the Healthcare Information Solutions division (PACS) of Carestream by Philips. Ludovic has been leading that business unit for seven years from Rochester, NY, USA. He previously ran the Business of Carestream in Europe after the General Electric's Healthcare IT business for France, Belgium and Luxembourg. His extensive experience and expertise offer a promising perspective for further achievement as a Chief Customer Officer overseeing Tribun Health's global sales and services to move forward a worldwide standard of quality.
"With the strong growth ahead in digital pathology, it became evident that we needed to find someone who could accelerate our business development across the world with first-class project delivery and customer care. We were looking for someone with cross-team communication and strategic planning as well as rigorous execution. It was obvious Ludovic was the right man, and I am so glad to have him on board," says Jean-François Pomerol, CEO at Tribun Health.
"I am thrilled to have joined Tribun Health as Executive Director and also shareholder. With an intimate pathology understanding, deep customer relationships, and innovative solutions powered by in-house AI capability, Tribun Health is an opportunity for me to bring my experience to a company that has a lot of growth potential. There are still many things to implement, which notably includes strengthening our teams across the globe with new talents. It is an honor to join that team at this extraordinary time," says Ludovic d'Apréa, New Chief Customer Officer at Tribun Health.
About Tribun Health: Tribun Health empowers confident decisions. The Paris-based, privately held company addresses a significant, fast-growing, and unmet need for expert end-to-end pathology departmental digitalization. Tribun Health is a pioneer in digital pathology workflow solutions with image acquisition (Macro), image storage/organization, web-based image management system (IMS), image analysis using AI-powered deep and machine learning algorithms, remote case sharing with peer review and report generation. Tribun Health's award-winning core platform, CaloPix, is considered the industry leader, winning the Best in Klas 2022 award for the most successful digital pathology provider in Europe. Tribun Health's extensive, decade-long expertise drives confidence for laboratories looking for a seamless transition to a digital pathology suite. https://www.tribun.health/
Original Source: Tribun Health Appoints Ludovic d'Apréa as Chief Customer Officer and Strengthens Its C-Level Global Team